Anti-CD20 monoclonal antibodies in multiple sclerosis

The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain

(2016) Lukas Haider et al.   BRAIN

CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma

(2016) John P. Leonard et al.   Clinical Lymphoma Myeloma & Leukemia

FCGR3A /2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts

(2016) Hervé Ghesquières et al.   HEMATOLOGICAL ONCOLOGY

Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses

(2016) Simon Faissner et al.   JOURNAL OF NEUROLOGY

Human memory B cells

(2016) M Seifert et al.   LEUKEMIA

MS arising during Tocilizumab therapy for rheumatoid arthritis

(2016) Philippe Beauchemin et al.   Multiple Sclerosis Journal

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

(2016) Pierre de Flon et al.   NEUROLOGY

Epidemiology of multiple sclerosis

(2016) E. Leray et al.   REVUE NEUROLOGIQUE

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

(2016) Rob N. de Jong et al.   PLOS BIOLOGY

MS arising during Tocilizumab therapy for rheumatoid arthritis

(2016) Philippe Beauchemin et al.   Multiple Sclerosis Journal

The effects of intrathecal rituximab on biomarkers in multiple sclerosis

(2016) Joanne Topping et al.   Multiple Sclerosis and Related Disorders

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis

(2016) Mika Komori et al.   Annals of Clinical and Translational Neurology

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

(2015) T. R. W. Tipton et al.   BLOOD

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

(2015) Aradhana Awasthi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis

(2015) Diana Ferraro et al.   JOURNAL OF NEUROIMMUNOLOGY

The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy

(2015) Chao Quan et al.   JOURNAL OF NEUROIMMUNOLOGY

Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis

(2015) L. Mozessohn et al.   JOURNAL OF VIRAL HEPATITIS

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*

(2015) Matt E. Kalaycio et al.   LEUKEMIA & LYMPHOMA

Macrophages are critical effectors of antibody therapies for cancer

(2015) Kipp Weiskopf et al.   mAbs

Ocrelizumab excites ECTRIMS

(2015) Ian Fyfe   Nature Reviews Neurology

Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica

(2015) Su-Hyun Kim et al.   JAMA Neurology

The Ins and Outs of B Cells in Multiple Sclerosis

(2015) Kevin Blauth et al.   Frontiers in Immunology

Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins

(2015) Simon N. Willis et al.   Frontiers in Immunology

The immune potential and immunopathology of cytokine-producing B cell subsets: A comprehensive review

(2014) Yan Bao et al.   JOURNAL OF AUTOIMMUNITY

Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis

(2014) P. V. Beum et al.   JOURNAL OF IMMUNOLOGY

BAFF Suppresses IL-15 Expression in B Cells

(2014) N. Ma et al.   JOURNAL OF IMMUNOLOGY

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

(2014) Arumugam Palanichamy et al.   JOURNAL OF IMMUNOLOGY

B cell follicle-like structures in multiple sclerosis—With focus on the role of B cell activating factor

(2014) Morten Haugen et al.   JOURNAL OF NEUROIMMUNOLOGY

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

(2014) Ludwig Kappos et al.   LANCET NEUROLOGY

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

(2014) Ping Shen et al.   NATURE

B cells with immune-regulating function in transplantation

(2014) Jessica Stolp et al.   Nature Reviews Nephrology

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Functional FCGR3A 158 V/F and IL-6 −174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis

(2014) Young Ho Lee et al.   RHEUMATOLOGY INTERNATIONAL

B cells in MS and NMO: pathogenesis and therapy

(2014) Markus Krumbholz et al.   Seminars in Immunopathology

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity

(2014) Klaus Lehmann-Horn et al.   Annals of Clinical and Translational Neurology

Specific peripheral B cell tolerance defects in patients with multiple sclerosis

(2013) Tuure Kinnunen et al.   JOURNAL OF CLINICAL INVESTIGATION

MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies

(2013) Nicolas Molnarfi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases

(2013) Viktoria Gredler et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies

(2013) Maria J Leandro   ARTHRITIS RESEARCH & THERAPY

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others

(2013) Hideaki Kobayashi et al.   Cancer Medicine

Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis

(2012) Christina Elliott et al.   BRAIN

Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis

(2012) Sung R. Choi et al.   BRAIN

Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models

(2012) Yukio Takeshita et al.   IMMUNOLOGICAL REVIEWS

Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity

(2012) Michael A. Maurer et al.   JOURNAL OF CLINICAL INVESTIGATION

B cell exchange across the blood-brain barrier in multiple sclerosis

(2012) H.-Christian von Büdingen et al.   JOURNAL OF CLINICAL INVESTIGATION

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells

(2012) Tom A. Barr et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation

(2012) Markus C Kowarik et al.   Journal of Neuroinflammation

The evidence for a role of B cells in multiple sclerosis

(2012) G. Disanto et al.   NEUROLOGY

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

(2011) David B. Clifford   ARCHIVES OF NEUROLOGY

Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells

(2011) Aharon Kessel et al.   AUTOIMMUNITY REVIEWS

Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis

(2011) Laura Lovato et al.   BRAIN

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis

(2011) Owain W. Howell et al.   BRAIN

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid

(2011) Samia Ragheb et al.   Multiple Sclerosis Journal

Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2011) I. Cortese et al.   NEUROLOGY

Inflammatory Cortical Demyelination in Early Multiple Sclerosis

(2011) Claudia F. Lucchinetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

(2011) Hans-Peter Tony et al.   ARTHRITIS RESEARCH & THERAPY

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity

(2010) Martin S. Weber et al.   ANNALS OF NEUROLOGY

Early Events in B Cell Activation

(2010) Naomi E. Harwood et al.   Annual Review of Immunology

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

B cell subsets in healthy children: Reference values for evaluation of B cell maturation process in peripheral blood

(2010) Barbara Piątosa et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4+ T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein

(2010) Christopher T. Harp et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Aggravated experimental autoimmune encephalomyelitis in IL-15 knockout mice

(2010) Diego Gomez-Nicola et al.   EXPERIMENTAL NEUROLOGY

Epstein-Barr Virus Latent Infection and BAFF Expression in B Cells in the Multiple Sclerosis Brain: Implications for Viral Persistence and Intrathecal B-Cell Activation

(2010) Barbara Serafini et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Ofatumumab

(2010) Bodi Zhang   mAbs

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

(2010) Mohsen Khademi et al.   Multiple Sclerosis Journal

Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis

(2010) S. A. Sargsyan et al.   NEUROLOGY

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)

(2010) Johannes Brettschneider et al.   PLoS One

CD20-Targeted Therapy: The Next Generation of Antibodies

(2010) Tom van Meerten et al.   SEMINARS IN HEMATOLOGY

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

Immunoglobulins and complement in postmortem multiple sclerosis tissue

(2009) Michael H. Barnett et al.   ANNALS OF NEUROLOGY

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab

(2009) Maria del Pilar Martin et al.   ARCHIVES OF NEUROLOGY

Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis

(2009) Laura A. N. Peferoen et al.   BRAIN

Monoclonal anti-CD20 antibodies: Mechanisms of action and monitoring of biological effects

(2009) Yves Renaudineau et al.   JOINT BONE SPINE

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

(2009) F. Sellebjerg et al.   NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity?

(2008) Sven Jarius et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

(2008) HF Petereit et al.   Multiple Sclerosis Journal

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

(2008) Satoshi Serada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA